A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC

In a recent manuscript published in Lung Cancer, Chao et al reported the results of the phase IIb NEOS study [1]. This multicenter open label single arm study evaluated the efficacy of neoadjuvant osimertinib in patients with stage IIA-IIIB (TNM 8th edition) resectable EGFR-mutant non-small cell lung cancer (NSCLC) [2]. The study demonstrated three key findings. First, of the 88 patients screened and 40 patients enrolled, 38 (95%) completed 6 weeks of planned neoadjuvant treatment with 71% (27/38) achieving an objective response (Fig.